Select a medication above to begin.
Comirnaty
COVID-19 vaccine, mRNA (1vCOV-mRNA)
Adult Dosing .
Dosage forms: INJ
Special Note
- [prescribing info]
- Info: see Pfizer-BioNTech COVID-19 Vaccine for Emergency Use Authorization in patients 6 mo-11 yo
COVID-19 prevention
- [immunocompetent or mildly immunocompromised patients, <65 yo]
- Dose: 0.3 mL IM x1 dose; Info: give at least 8wk after last COVID-19 vaccine dose if previously vaccinated; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [immunocompetent or mildly immunocompromised patients, 65 yo and older]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Info: give at least 8wk after last COVID-19 vaccine dose if previously vaccinated; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [moderately-severely immunocompromised patients, not previously vaccinated]
- Dose: 0.3 mL IM x2 doses 3wk apart, then 0.3 mL IM x1 dose at least 4wk later, then 0.3 mL IM x1 dose at least 6mo later; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [moderately-severely immunocompromised patients, previously received 1 Pfizer-BioNTech vaccine dose]
- Dose: 0.3 mL IM x2 doses at least 4wk apart, then 0.3 mL IM x1 dose at least 6mo later; Start: 3wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [moderately-severely immunocompromised patients, previously received 2 Pfizer-BioNTech vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 4wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [moderately-severely immunocompromised patients, previously received 3 or more mRNA vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 8wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
- [moderately-severely immunocompromised patients, previously received 2 or more Novavax vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 8wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Adult Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Peds Dosing .
- Dosage forms: INJ
Special Note
- [prescribing info]
- Info: see Pfizer-BioNTech COVID-19 Vaccine for Emergency Use Authorization in patients 6 mo-11 yo
COVID-19 prevention
- [12 yo and older, immunocompetent or mildly immunocompromised patients]
- Dose: 0.3 mL IM x1 dose; Info: give at least 8wk after last COVID-19 vaccine dose if previously vaccinated; ACIP recommends shared clinical decision-making; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [12 yo and older, moderately-severely immunocompromised patients, not previously vaccinated]
- Dose: 0.3 mL IM x2 doses 3wk apart, then 0.3 mL IM x1 dose at least 4wk later, then 0.3 mL IM x1 dose at least 6mo later; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [12 yo and older, moderately-severely immunocompromised patients, previously received 1 Pfizer-BioNTech vaccine dose]
- Dose: 0.3 mL IM x2 doses at least 4wk apart, then 0.3 mL IM x1 dose at least 6mo later; Start: 3wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [12 yo and older, moderately-severely immunocompromised patients, previously received 2 Pfizer-BioNTech vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 4wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [12 yo and older, moderately-severely immunocompromised patients, previously received 3 or more mRNA vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 8wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
- [12 yo and older, moderately-severely immunocompromised patients, previously received 2 or more Novavax vaccine doses]
- Dose: 0.3 mL IM x2 doses at least 6mo apart; Start: at least 8wk after last dose; Info: may give additional dose at least 2mo after last dose and consider further doses on case-by-case basis; search 'immunization' for epocrates Child/Adolescent Immunization decision tool incl. links to CDC/ACIP schedules
renal dosing
- [no adjustment]
- renal impairment: no adjustment
- HD/PD: no adjustment; no supplement
hepatic dosing
- [no adjustment]
Contraindications / Cautions .
- hypersensitivity to drug or ingredient
- hypersensitivity to other mRNA COVID-19 vaccines
- caution: non-severe hypersensitivity to prior mRNA COVID-19 vaccine dose
- caution: non-severe hypersensitivity to mRNA COVID-19 vaccine component
- caution: hypersensitivity to vector COVID-19 vaccine
- caution: hypersensitivity to protein subunit COVID-19 vaccine
- caution: immunocompromised patients
- caution: male patients <40 yo
- caution: multisystem inflammatory syndrome history
- caution: myocarditis w/in 3wk of prior COVID-19 vaccine
- caution: pericarditis w/in 3wk of prior COVID-19 vaccine
- caution: illness, acute moderate-severe
Drug Interactions .
Overview
COVID-19 vaccine
vaccine
- non-live vaccine
Avoid/Use Alternative
- interferon gamma 1b
Monitor/Modify Tx
- abatacept
- abemaciclib
- abrocitinib
- acalabrutinib
- adalimumab
- ado-trastuzumab emtansine
- afamitresgene autoleucel
- aldesleukin
- alemtuzumab
- anakinra
- anifrolumab
- anti-thymocyte globulin
- atezolizumab
- atidarsagene autotemcel
- avelumab
- avutometinib
- axicabtagene ciloleucel
- azacitidine
- azathioprine
- baricitinib
- basiliximab
- belatacept
- belimumab
- belinostat
- belzutifan
- bendamustine
- betamethasone
- bimekizumab
- blinatumomab
- bortezomib
- brentuximab vedotin
- brexucabtagene autoleucel
- brodalumab
- budesonide
- budesonide rectal
- busulfan
- cabazitaxel
- canakinumab
- capecitabine
- capmatinib
- carboplatin
- carfilzomib
- carmustine
- cemiplimab
- certolizumab pegol
- chlorambucil
- ciltacabtagene autoleucel
- cisplatin
- cladribine injection
- cladribine oral
- clofarabine
- copanlisib
- corticotropin
- cortisone
- cosibelimab
- cyclophosphamide
- cyclosporine
- cytarabine
- dactinomycin
- daratumumab
- dasatinib
- daunorubicin
- decitabine
- defactinib
- deflazacort
- delgocitinib topical
- deucravacitinib
- deuruxolitinib
- dexamethasone
- dimethyl fumarate
- dinutuximab
- diroximel fumarate
- docetaxel
- dordaviprone
- dostarlimab
- doxorubicin
- dupilumab
- durvalumab
- duvelisib
- efgartigimod alfa
- elivaldogene autotemcel
- elotuzumab
- elranatamab
- emapalumab
- epcoritamab
- epirubicin
- eribulin
- etanercept
- etoposide
- etrasimod
- everolimus
- fam-trastuzumab deruxtecan
- fingolimod
- floxuridine
- fludarabine
- fludrocortisone
- fluorouracil
- fruquintinib
- gemcitabine
- gemtuzumab ozogamicin
- glofitamab
- golimumab
- guselkumab
- hydrocortisone
- hydroxyurea
- ibritumomab tiuxetan
- ibrutinib
- idarubicin
- idecabtagene vicleucel
- idelalisib
- ifosfamide
- imatinib
- inebilizumab
- infliximab
- inotuzumab ozogamicin
- ipilimumab
- irinotecan
- isatuximab
- ixabepilone
- ixekizumab
- lebrikizumab
- leflunomide
- lenalidomide
- linvoseltamab
- lisocabtagene maraleucel
- lomustine
- loncastuximab tesirine
- lurbinectedin
- lymphocyte immune globulin, anti-thymocyte globulin
- margetuximab
- melphalan
- mercaptopurine
- methotrexate
- methylprednisolone
- mirikizumab
- mitomycin
- mitoxantrone
- mogamulizumab
- momelotinib
- monomethyl fumarate
- mosunetuzumab
- mycophenolate mofetil
- mycophenolic acid
- natalizumab
- nelarabine
- nemolizumab
- nilotinib
- nipocalimab
- nivolumab
- obecabtagene autoleucel
- obinutuzumab
- ocrelizumab
- ofatumumab
- oxaliplatin
- ozanimod
- paclitaxel
- palbociclib
- panobinostat
- peginterferon alfa 2a
- pembrolizumab
- pemivibart
- pentostatin
- pertuzumab
- pirtobrutinib
- polatuzumab vedotin
- pomalidomide
- ponatinib
- ponesimod
- prednisolone
- prednisone
- procarbazine
- regorafenib
- retifanlimab
- rilonacept
- ripretinib
- risankizumab
- ritlecitinib
- rituximab
- romidepsin
- ropeginterferon alfa-2b
- rozanolixizumab
- ruxolitinib
- sarilumab
- satralizumab
- secukinumab
- selinexor
- siltuximab
- siponimod
- sirolimus
- sirolimus albumin-bound
- sirolimus topical
- smallpox vaccine, live
- smallpox/mpox vaccine, live
- spesolimab
- sunitinib
- sunvozertinib
- tacrolimus
- tafasitamab
- talquetamab
- tarlatamab
- teclistamab
- temozolomide
- temsirolimus
- teplizumab
- teriflunomide
- thioguanine
- thiotepa
- tildrakizumab
- tisagenlecleucel
- tislelizumab
- tocilizumab
- tofacitinib
- topotecan
- toripalimab
- tralokinumab
- tremelimumab
- triamcinolone
- ublituximab
- upadacitinib
- ustekinumab
- vamorolone
- vandetanib
- vedolizumab
- venetoclax
- vinblastine
- vincristine
- vinorelbine
- voclosporin
- zanidatamab
- zanubrutinib
- zenocutuzumab
- zongertinib
Adverse Reactions .
Serious Reactions
- hypersensitivity rxn
- anaphylaxis
- Bell palsy
- myocarditis
- pericarditis
Common Reactions
- injection site rxn
- fatigue
- headache
- myalgia
- chills
- arthralgia
- fever
- diarrhea
- vomiting
- lymphadenopathy
- dizziness
Safety/Monitoring .
Monitoring Parameters
no routine tests recommended
Pregnancy/Lactation .
Pregnancy
Clinical Summary
may use during pregnancy; no known risk of fetal harm based on limited human data
Pregnancy Registry
encourage patients to enroll in COVID-19 Vaccines Pregnancy Registry at https://mothertobaby.org/ongoing-study/covid19-vaccines/; encourage patients to enroll in COVID-19 Vaccines International Pregnancy Exposure Registry at https://cviper.pregistry.com; encourage patients to enroll in v-safe COVID-19 Vaccine Pregnancy Registry at https://vsafe.cdc.gov
Lactation
Clinical Summary
may use while breastfeeding; no human data available, though risk of infant harm not expected based on vaccine properties; no human data available to assess effects on milk production
Pharmacology .
Metabolism: other; CYP450: unknown
Excretion: other; Half-life: unknown
Subclass: Coronavirus Vaccines ; Routine Adult Vaccines ; Routine Pediatric Vaccines
Mechanism of Action
elicits humoral and cellular immune response to the SARS-CoV-2 virus
Formulary .
No Formulary Selected
Join Now to View Patient Handouts!
Create a FREE epocrates Online account to access patient medication instructions. Your patients and caregivers will appreciate you printing these friendly handouts, available in English and Spanish. Each handout addresses common concerns such as how to take the medication, and possible side effects.
Current Members: Sign In.
Pill Pictures
Join Now to View Pill Pictures!
Create a FREE epocrates Online account to access full-color images of medications within the drug monograph.
Current Members: Sign In.